We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-15.01%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$461M
AUM Growth
-$222M
Cap. Flow
-$108M
Cap. Flow %
-23.46%
Top 10 Hldgs %
59.88%
Holding
143
New
25
Increased
20
Reduced
27
Closed
54

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$24.9M
2
VTRS icon
Viatris
VTRS
+$13.9M
3
ITRN icon
Ituran Location and Control
ITRN
+$8.4M
4
PFE icon
Pfizer
PFE
+$7.53M
5
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$4.18M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$21.4M
2
BMY icon
Bristol-Myers Squibb
BMY
+$8.36M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$6.09M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$5.76M
5
INCY icon
Incyte
INCY
+$5.6M

Sector Composition

Rank Sector Weight
1 Healthcare 62.23%
2 Technology 3.77%
3 Utilities 2.89%
4 Communication Services 2.27%
5 Financials 1.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNS
26
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3.07M 0.67%
142,727
– –
PTNR
27
DELISTED
Partner Communications
PTNR
$2.91M 0.63%
624,230
+6,279
+1% +$28K
MGNX icon
28
MacroGenics
MGNX
$235M
$2.87M 0.62%
153,000
– –
RDUS
29
DELISTED
Radius Health, Inc.
RDUS
$2.83M 0.61%
90,000
+20,000
+29% +$692K
PANW icon
30
Palo Alto Networks
PANW
$270B
$2.8M 0.61%
+103,050
New +$2.53M
GNCA
31
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.8M 0.61%
45,239
-22,322
-33% -$709K
NBIX icon
32
Neurocrine Biosciences
NBIX
$16.8B
$2.77M 0.6%
+70,000
New +$2.78M
ZVRA icon
33
Zevra Therapeutics
ZVRA
$562M
$2.67M 0.58%
11,497
– –
FOLD
34
DELISTED
Amicus Therapeutics
FOLD
$2.54M 0.55%
+300,000
New +$2.12M
FOLD
35
PUT
DELISTED
Amicus Therapeutics
FOLD
$2.54M 0.55%
+300,000
New +$2.12M
DERM
36
DELISTED
Dermira, Inc.
DERM
$2.48M 0.54%
+120,000
New +$2.94M
EIGR
37
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.47M 0.54%
+4,917
New +$2.45M
CYTK icon
38
Cytokinetics
CYTK
$10.5B
$2.41M 0.52%
+341,944
New +$2.5M
NDRM
39
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$2.35M 0.51%
+166,359
New +$2.25M
KITE
40
DELISTED
Kite Pharma, Inc.
KITE
$2.3M 0.5%
50,000
– –
ACAD icon
41
PUT
Acadia Pharmaceuticals
ACAD
$4.43B
$2.24M 0.48%
+80,000
New +$1.74M
FOMX
42
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.23M 0.48%
342,000
– –
KDNY
43
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.18M 0.47%
34,000
+10,000
+42% +$809K
APD icon
44
Air Products & Chemicals
APD
$65.7B
$2.11M 0.46%
+15,860
New +$1.92M
CHMA
45
DELISTED
Chiasma, Inc. Common Stock
CHMA
$2.11M 0.46%
+230,649
New +$2.5M
FWP
46
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$2.07M 0.45%
17,357
– –
AGIO icon
47
Agios Pharmaceuticals
AGIO
$1.79B
$2.03M 0.44%
50,000
– –
CBIO
48
Crescent Biopharma
CBIO
$535M
$2.01M 0.44%
+3,379
New +$1.73M
EGLT
49
DELISTED
Egalet Corporation
EGLT
$2.01M 0.44%
292,500
– –
MLNX
50
DELISTED
Mellanox Technologies, Ltd.
MLNX
$2M 0.43%
+36,760
New +$1.7M
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2016 Portfolio in Review

As of Q1 2016, Sphera Funds Management held 143 positions worth $461M, down 32% from $683M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sphera Funds Management withdrew a net $108M in Q1 2016, closing 54 positions and reducing 27 holdings. Its most notable exit was AbbVie, an estimated $21.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, up from 61% a quarter earlier, followed by Technology and Utilities.

Against the trend, Sphera Funds Management opened a new position in Viatris worth $13.3M.

  • Sphera Funds Management's largest Q1 2016 buy was Viatris: 287,827 shares worth $13.3M.
  • Sphera Funds Management added most to Shire pic in Q1 2016, an estimated $24.9M increase.
  • Sphera Funds Management's biggest Q1 2016 reduction was Celgene Corp, cutting an estimated $4.86M.
  • Sphera Funds Management fully exited AbbVie in Q1 2016, selling an estimated $21.4M.
  • Sphera Funds Management's ten largest holdings make up 60% of its $461M portfolio in Q1 2016.
  • Sphera Funds Management opened 25 new positions and closed 54 in Q1 2016.
  • Sphera Funds Management's portfolio value fell 32% quarter-over-quarter to $461M.

Based on Sphera Funds Management's 13F filing for Q1 2016, filed 16 May 2016.